Ayala Pharmaceuticals Announces Presentation at the European Society for Medical Oncology (ESMO)

Presentation information is as follows:

Title: ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch^{act mut}): preliminary safety and efficacy data
Session Title: Poster Display Session
Session Date and Time: Monday, September 30, 2019 at 12:00pm to 1:00pm CET
Presentation Number: 1148P
Location: Poster Area (Hall 4)
Presenter: Alan L. Ho, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102). Ayala’s lead product candidate, AL101, is currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations (ACCURACY). For more information, visit www.ayalapharma.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190919005544/en/